Using Recombinant Factor VII for Severe Bleeding After Heart Surgery
Author Information
Author(s): Gandhi Manish J, Pierce Richard A, Zhang Lini, Moon Marc R, Despotis George J, Moazami Nader
Primary Institution: Washington University School of Medicine
Hypothesis
Can recombinant activated factor VII (rFVIIa) effectively control severe hemorrhage in patients undergoing orthotopic heart transplant and/or ventricular assist device implantation?
Conclusion
The use of rFVIIa significantly reduced blood loss and transfusion requirements in patients with severe bleeding, although some patients experienced thromboembolic complications.
Supporting Evidence
- Blood loss significantly decreased from an average of 698 ml/hr to 136 ml/hr after rFVIIa administration.
- Transfusion requirements for packed red blood cells dropped from 16.9 units to 7.1 units after treatment.
- Five out of 17 patients experienced thromboembolic complications, including three fatalities.
Takeaway
Doctors used a special medicine called rFVIIa to help stop bleeding in patients after heart surgery, and it worked well, but some patients had problems with blood clots.
Methodology
A retrospective review of patients who received rFVIIa for intractable bleeding unresponsive to standard therapy, with data on blood loss and transfusion recorded before and after treatment.
Potential Biases
Potential bias due to the retrospective nature of the study and the lack of a control group.
Limitations
The study was retrospective and involved a small sample size, which may limit the generalizability of the findings.
Participant Demographics
Mean age was 53 years, with 73% male and all patients being Caucasian.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 3.9–17.0
Statistical Significance
p<0.04
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website